Dobson | DaVanzo is pleased to announce that we were recently awarded the Medicare Part D Claims Analyses contract with the Centers for Medicare and Medicaid Services (CMS). This project supports CMS in managing and providing oversight of the Part D benefit through a variety of analyses that assess the program, its impact on the health outcomes of beneficiaries, and the implications of future policy changes. Together with our subcontractor, Acumen, LLC, we look forward to supporting CMS in this important work through our analyses that monitor and measure the compliance of Medicare Part D sponsors with federal regulations.
We also are proud to announce a recently published study in The Undersea and Hyperbaric Medicine Journal, entitled, “Controlled CMS Data Demonstrates a Cost and Clinical Advantage for Hyperbaric Oxygen and Radiation Cystitis.” Recent advances in radiation therapy have led to dramatic increases in cancer survivorship over recent decades, creating a larger population at risk for delayed complications stemming from radiation treatments, such as radiation cystitis.
Dobson | DaVanzo, in conjunction with Undersea and Hyperbaric Medical Society (UHMS), assessed the clinical outcomes and cost effectiveness of hyperbaric oxygen treatment (HBO2) for radiation cystitis compared to conventional care. Among findings, D|D identified that treatment group beneficiaries had almost $11,548 lower total Medicare spending due to Hyperbaric Oxygen Therapy relative to the comparison group, representing a 37% reduction in spending over the first year post-HBO2 relative to average spending in the pre-period.
Not Yet a Premium Partner/Sponsor? Learn more about the OS AI Premium Corporate and Individual Plans here. Plans start at $250 annually.
